Item Number: CANIPARC
Canigen Parvo-C Immunisation Vaccine for Dogs (10 dose).
For active immunisation of dogs to prevent mortality, clinical signs and viral excretion following canine parvovirus infection.
An onset of immunity of 1 week has been demonstrated following use of the vaccine.
A duration of immunity of at least three years has been established for the vaccine.
Dosage and administration
The contents of one vial of reconstituted vaccine should be injected subcutaneously. Reconstitute immediately prior to use by the addition of the contents of one vial (1.0 ml) of Canigen Lepto 2 (canine leptospirosis vaccine), Canigen Rabies, or Canigen Solvent.
Avoid contamination of vaccine with traces of chemical sterilising agents. Do not use chemicals such as disinfectant or spirit to disinfect the skin prior to inoculation.
Primary course vaccination
A single injection should establish active immunity to disease caused by canine parvovirus infection in dogs of 10 weeks of age or older. Where earlier protection is required a first dose may be given to puppies from 4 weeks of age, but because maternally derived passive antibody can interfere with the response to vaccination a final dose at 10 weeks of age or older is generally recommended.
It is recommended that dogs be revaccinated every 3 years.
Experience has shown that the maternal antibody status of pups within a litter varies greatly and reliance should not be placed on serological examination of the bitch alone.
A good immune response is reliant on the reaction of an immunogenic agent and a fully competent immune system. The immunogenicity of the vaccine antigen will be reduced by poor storage or inappropriate administration. Immunocompetence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress.
Can be used in pregnant bitches which have previously been vaccinated with the CPV (strain 154) antigens included in the Canigen vaccine series.
Contra-indications, warnings, etc
Do not use in unhealthy dogs. The vaccine may not be effective in dogs incubating the disease at the time of vaccination.
Some animals may be immunologically incompetent and fail to respond to vaccination. Animals that have received the corresponding anti-serum or immunosuppressive drugs should not be vaccinated until an interval of at least 4 weeks has elapsed.
A diffuse swelling, up to 5 mm in diameter, may be observed at the site of injection. Occasionally this swelling may be hard and painful and last for up to 3 days post injection.
After subcutaneous administration with a Virbac vaccine containing Rabies and/or Lepto 2 antigens, a transient palpable nodule may occasionally occur at the site of injection.
In the rare event of a hypersensitivity reaction occurring following vaccination, administer an antihistamine, corticosteroid or adrenaline, without delay and by the most immediate route.
After administration of an overdose, a response similar to that following a single dose may be seen. In some dogs the swelling may be more painful or may be observed for a longer period.
If you notice any serious effects not mentioned on this leaflet, please inform your veterinary surgeon.
The vaccine strain may be shed at very low levels for up to 8 days after inoculation. However there is no evidence of any reversion to virulence of the vaccine strain and therefore no need to separate unvaccinated dogs from contact with recently vaccinated individuals.
Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day with Canigen Solvent, Canigen Lepto 2 or Canigen Rabies. These can be used to reconstitute the freeze-dried Canigen Parvo-C. No information is available on the saefty and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Do not mix with any other medicinal product except Canigen Lepto 2, Canigen Solvent or Canigen Rabies.
The efficacy of the CPV component of the vaccine may be reduced due to maternal antibody interference. However, the vaccine has been proven to be of benefit against virulent challenge in the presence of maternal antibody levels to CPV that are likely to be encountered under field conditions.
For animal treatment only. Keep out of reach and sight of children.
Store in a refigerator at between +2°C and +8°C. Do not freeze. Store out of light.
Care should be taken to avoid prolonged or repetitive exposure to high ambient temperatures following withdrawal from the refrigerator prior to use - in hot summer conditions vaccine potency can be severely reduced within a few hours.
After reconstitution use within 30 minutes.
Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant approved for use by the competent authorities.
POM-V To be supplied only on veterinary prescription
Clear, Glass Type I (PhEur) single vials with halogenobutyl rubber stopper, closed with a colour-coded aluminium cap. Cartons containing 10 or 50 vials. Not all presentations may be marketed
CANIPARC: Data Sheet